Biohaven Ltd. (NYSE:BHVN) Position Increased by Janus Henderson Group PLC

Janus Henderson Group PLC raised its holdings in shares of Biohaven Ltd. (NYSE:BHVN) by 5.6% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 6,226,393 shares of the company’s stock after purchasing an additional 328,099 shares during the period. Janus Henderson Group PLC owned about 6.16% of Biohaven worth $311,142,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently modified their holdings of BHVN. DNB Asset Management AS acquired a new position in shares of Biohaven during the second quarter valued at $285,000. CWM LLC boosted its holdings in shares of Biohaven by 1,893.4% during the second quarter. CWM LLC now owns 14,552 shares of the company’s stock valued at $505,000 after acquiring an additional 13,822 shares during the period. SG Americas Securities LLC boosted its holdings in shares of Biohaven by 114.6% during the second quarter. SG Americas Securities LLC now owns 25,255 shares of the company’s stock valued at $877,000 after acquiring an additional 13,485 shares during the period. Oak Ridge Investments LLC boosted its holdings in shares of Biohaven by 197.6% during the second quarter. Oak Ridge Investments LLC now owns 22,000 shares of the company’s stock valued at $764,000 after acquiring an additional 14,607 shares during the period. Finally, ARS Investment Partners LLC lifted its holdings in Biohaven by 47.8% in the second quarter. ARS Investment Partners LLC now owns 940,512 shares of the company’s stock worth $32,645,000 after purchasing an additional 304,141 shares during the period. Institutional investors and hedge funds own 88.78% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on the stock. William Blair raised shares of Biohaven to a “strong-buy” rating in a report on Friday, August 30th. Royal Bank of Canada reduced their price objective on shares of Biohaven from $66.00 to $58.00 and set an “outperform” rating for the company in a report on Monday, November 25th. TD Cowen upped their price objective on shares of Biohaven from $55.00 to $75.00 and gave the stock a “buy” rating in a report on Wednesday, November 13th. Sanford C. Bernstein upped their price objective on shares of Biohaven from $55.00 to $66.00 and gave the stock an “outperform” rating in a report on Tuesday, September 24th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Biohaven in a report on Wednesday, October 23rd. Thirteen analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $62.75.

Insiders Place Their Bets

In other Biohaven news, Director Gregory Bailey bought 5,000 shares of the company’s stock in a transaction dated Tuesday, September 24th. The shares were bought at an average price of $44.19 per share, for a total transaction of $220,950.00. Following the acquisition, the director now directly owns 1,620,071 shares of the company’s stock, valued at approximately $71,590,937.49. This trade represents a 0.31 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director John W. Childs bought 21,052 shares of the company’s stock in a transaction dated Wednesday, October 2nd. The stock was acquired at an average price of $47.50 per share, for a total transaction of $999,970.00. Following the acquisition, the director now directly owns 21,052 shares in the company, valued at $999,970. This trade represents a ∞ increase in their ownership of the stock. The disclosure for this purchase can be found here. Corporate insiders own 16.00% of the company’s stock.

Biohaven Trading Down 2.4 %

NYSE BHVN opened at $43.68 on Wednesday. The stock’s 50-day moving average price is $49.71 and its two-hundred day moving average price is $41.52. The company has a market cap of $4.42 billion, a PE ratio of -4.67 and a beta of 1.24. Biohaven Ltd. has a 1 year low of $26.80 and a 1 year high of $62.21.

Biohaven (NYSE:BHVN) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($1.70) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.67) by ($0.03). Research analysts forecast that Biohaven Ltd. will post -8.85 EPS for the current fiscal year.

Biohaven Company Profile

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.